IMV Inc. Files Preliminary Prospectus Supplement for Proposed Public Offering of Common Shares
01 March 2019 - 8:51AM
IMV Inc. (“IMV” or the “Corporation”) (NASDAQ: IMV; TSX: IMV),
a clinical-stage immuno-oncology corporation, has today filed a
preliminary prospectus supplement (the “Supplement”) to its
short form base shelf prospectus dated June 5, 2018
(the “Base Prospectus”) in connection with a proposed public
offering of its common shares (the “Offering”). The Supplement
was filed with the securities regulatory authorities in the
provinces of British Columbia, Alberta, Saskatchewan, Manitoba,
Ontario, Québec, Nova Scotia and Newfoundland and Labrador. The
Supplement was also filed with the U.S. Securities and Exchange
Commission (the “SEC”) as part of a registration statement on
Form F-10, as amended (the “Registration Statement”), which
was declared effective by the SEC on June 6, 2018, in accordance
with the Multijurisdictional Disclosure System established between
Canada and the United States.
The Corporation intends to use the net proceeds
of the Offering to accelerate the development of DPX-Survivac in
combination with Keytruda as part of the basket trial select
advanced or recurrent solid tumours in bladder, liver
(hepatocellular carcinoma), ovarian or non-small-cell lung cancers,
as well as tumours shown to be positive for the microsatellite
instability high biomarker and for general corporate purposes.
The Corporation also expects to grant to the
underwriters a 30-day option to purchase up to an additional 15% of
the number of common shares offered in the Offering. The Offering
is expected to be priced in the context of the market, with the
final terms of the Offering to be determined at the time of
pricing. There can be no assurance as to whether or when the
Offering may be completed, or as to the actual size or terms of the
Offering. The closing of the Offering will be subject to customary
closing conditions, including the listing of the common shares on
the TSX and Nasdaq and any required approvals of each exchange.
Wells Fargo Securities and Raymond James are
acting as joint book-running managers for the Offering. B. Riley
FBR is acting as co-manager.
The Supplement and the accompanying Base
Prospectus contain important detailed information about the
Offering. The Supplement and the accompanying Base Prospectus can
be found for free on SEDAR at www.sedar.com and on EDGAR at
www.sec.gov. Copies of the Supplement and accompanying Base
Prospectus may also be obtained from Wells Fargo Securities, Attn:
Equity Syndicate, 375 Park Avenue, New York, NY 10152, by
telephone at (800) 326-5897, or by email
at cmclientsupport@wellsfargo.com or from Raymond James, Attn:
Equity Syndicate, 880 Carillon Parkway, St. Petersburg, Florida
33716, or by telephone at (800) 248-8863, or e-mail at
prospectus@raymondjames.com. Prospective investors should read the
Supplement and accompanying Base Prospectus and the other documents
the Corporation has filed before making an investment decision.
This news release shall not constitute an offer
to sell or the solicitation of an offer to buy, nor shall there be
any sale of these securities in any province, state or jurisdiction
in which such offer, solicitation or sale would be unlawful prior
to the registration or qualification under the securities laws of
any such province, state or jurisdiction.
About IMV Inc.
IMV Inc. is a clinical stage biopharmaceutical
company dedicated to making immunotherapy more effective, more
broadly applicable, and more widely available to people facing
cancer and other serious diseases. IMV is pioneering a new class of
immunotherapies based on the Corporation’s proprietary drug
delivery platform. This patented technology leverages a novel
mechanism of action that enables the programming of immune cells in
vivo, which are aimed at generating powerful new synthetic
therapeutic capabilities. IMV’s lead candidate, DPX-Survivac, is a
T cell-activating immunotherapy that combines the utility of the
platform with a target: survivin. IMV is currently assessing
DPX-Survivac as a monotherapy in advanced ovarian cancer, as well
as a combination therapy in multiple clinical studies in
collaboration with Merck.
Cautionary Note Regarding Forward
Looking Statements
This press release contains forward-looking
information under applicable securities law. All information that
addresses activities or developments that we expect to occur in the
future is forward-looking information. Forward-looking statements
are based on the estimates and opinions of management on the date
the statements are made. In the press release, such forward-looking
statements include, but are not limited to, statements regarding
the Offering, the anticipated size of the Offering, the granting of
the over-allotment option and the anticipated use of proceeds from
the Offering. However, they should not be regarded as a
representation that any of the plans will be achieved. Actual
results may differ materially from those set forth in this press
release due to known and unknown risks and uncertainties affecting
the Corporation, including market conditions, access to capital,
the successful design and completion of clinical trials and the
receipt and timely receipt of all regulatory approvals and other
risks detailed from time to time in our ongoing quarterly filings
and annual information form. IMV Inc. assumes no
responsibility to update forward-looking statements in this press
release except as required by law. Investors are cautioned
not to rely on these forward-looking statements and are encouraged
to read IMV’s continuous disclosure documents, including its
current annual information form, as well as its audited annual
consolidated financial statements which are available on SEDAR
at www.sedar.com and on EDGAR
at www.sec.gov/edgar.
Contacts for IMV:
MEDIA Andrea Cohen, Sam Brown Inc.
T: (917) 209-7163 E: AndreaCohen@sambrown.com
INVESTOR RELATIONS Marc Jasmin,
IMV Senior Director, Investor Relations T: (902) 492-1819
E: info@imv-inc.com
IMV (TSX:IMV)
Historical Stock Chart
From Jun 2024 to Jul 2024
IMV (TSX:IMV)
Historical Stock Chart
From Jul 2023 to Jul 2024